Alembic Pharmaceutical, a Vadodara based pharma major with net sales of Rs.3,100 plus, has posted impressive performance during the fourth quarter ended March 2016 and its consolidated net sales increased by 29.6 per cent to Rs.91.18 crore from Rs.70.33 crore in the corresponding period of last year. Its EBDITA moved up by 46.2 per cent to Rs.145.92 crore from Rs.99.80 crore. The company declared equity dividend of 200 per cent for the year 2015-16.
Its consolidated net sales increased by 24.7 per cent to Rs.625.55 crore from Rs.501.83 crore. Its domestic sales increased by 7.5 per cent to Rs.296.05 crore from Rs.275.30 crore and its exports moved up sharply by 45.3 per cent to Rs.338.11 crore from Rs.232.65 crore. Its international formulation sales increased by 20 per cent to Rs.190.18 crore from Rs.158.35 crore. Similarly, Indian branded sales improved by 12 per cent to Rs.259.63 crore from Rs.232.08 crore. However, its Indian generic sales declined by 46 per cent to Rs.17.44 crore from Rs.32.09 crore. API sales increased by 95 per cent to Rs.166.91 crore from Rs.85.43 crore.
Pranav Amin, managing director, said, “This has been an outstanding year for the company. R&D will continue to remain a thrust area and we hope to strengthen our portfolio rapidly in the years to come. The recent JV with Orbicula will help establish our presence in the dermatology segment.”
For the full year ended March 2016, Alembic's consolidated net sales increased by 53.2 per cent to Rs.3,145 crore from Rs.2,053 crore in the previous year. Its net profit went up sharply by 154 per cent to Rs.719.44 crore from Rs.282.93 crore and EBDITA moved up by 150 per cent to Rs.1,011 crore from Rs.405 crore. R&D expenditure increased by 154 per cent to Rs.307.06 crore from Rs.121.62 crore.
The sales of formulation in International market increased by 146 per cent to Rs.1,461 crore from Rs.593 crore in the previous year. The company launched 11 new product in US and set up a new office in US. The sales of branded products in domestic market increased by 13 per cent to Rs.1,104 crore from Rs.981 crore. The generic sales in India declined by 26 per cent to Rs.91.18 crore from Rs.122.74 crore. Its API sales increased by 42 per cent to Rs.524.94 crore from Rs.370.67 crore. Specialty segment grew by 20 per cent.
It filed 8 ANDAs and cumulative ANDA filings reached at 76. Similarly, it filed 9 DMF applications and its cumulative DMF filings reached at 81. R&D expenditure for the year 2015-16 increased by 154 per cent to Rs.307.06 crore from Rs.121.62 crore.
As against the equity capital of Rs.37.70 crore, its reserves & surplus amounted to Rs.1,562.84 crore, a growth of 84.5 per cent.